ArticleFrontiers in neurology
Combination of flupentixol and melitracen tablets and rTMS improves post-stroke depression through neurovegetative symptoms changes: a retrospective analysis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke depression (PSD) is one of the most common neuropsychiatric complications among stroke survivors, with a substantial impact on functional recovery and quality of life. This study aimed to investigate the effect of flupentixol and melitracen tablets combined with repetitive transcranial magnetic stimulation (rTMS) on patients with post-stroke depression (PSD) and analyze the differences in the key factors of the 17-item Hamilton Depression Scale (HAMD Methods: We conducted a retrospective analysis of 121 patients with PSD, including 57 patients who used the flupentixol and melitracen tablets alone and 64 patients who additionally received rTMS. General information was assessed. Follow-up indices after treatment included P300, National Institutes of Health Stroke Scale (NIHSS), HAMD Results: There was significant difference in the amplitude and latency of P300 and NS after 2 weeks and 4 weeks treatment between the groups, while there was significant difference in the concentrations of 5-HT, NE, NPY, BDNF and the scores of NIHSS, HAMD Conclusion: Combination of flupentixol and melitracen tablets and rTMS could significantly improve the depressive symptoms of patients with PSD, NS was the symptom dimension most closely related to the therapeutic response. More importantly, the P300 parameter might provide an early and objective indicator of the neurophysiological changes associated with the treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.